Coronary Artery DiseasePCI-CAMPOSNCT02022345
Safety and Efficacy of PCI at California Hospitals Without Onsite Cardiac Surgery
A study testing Percutaneous Coronary Intervention in people with Coronary Artery Disease, run by University of California, Davis at 6 sites in United States.
Trial summary
To evaluate the introduction of Percutaneous Coronary Intervention without Onsite Surgery in the largest state, California (CA) began a pilot PCI program in 6 hospitals without onsite cardiac surgery and then compared the PCI results in the pilot hospitals with results in 120 non-pilot hospitals. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Coronary Artery Disease
- What is being tested?
- Percutaneous Coronary Intervention
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5,609 participants
- Where
- 6 sitesUnited States
- Study dates
- Aug 2010to Feb 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- clinically and angiographically significant coronary artery disease
- ability to perform PCI with equipment available at the local site
- not high-risk patient with a not high-risk lesion
- not high-risk patient with a high-risk lesion
- high-risk patient with a not high-risk lesion may be included in the pilot program upon confirmation that a cardiac surgeon and an operating room are immediately available if necessary
Who cannot join
- high-risk patient with a high-risk lesion
- need for coronary artery bypass surgery
Trial locations and contacts
6 sites in 1 country.
6 sites in 1 country
United States6 sites
Clovis Community Medical Center
Clovis, California, 93611
St Rose Hospital
Hayward, California, 94545
Los Alamitos Medical Center
Los Alamitos, California, 90720
Sutter Roseville Medical Center
Roseville, California, 95661
Doctors Medical Center
San Pablo, California, 94806
Kaiser Foundation Hospital Walnut Creek
Walnut Creek, California, 94596
About this study
Official title: PCI California Audit Monitored Pilot With Offsite Surgery
To evaluate the introduction of Percutaneous Coronary Intervention without Onsite Surgery in the largest state, California (CA) began a pilot PCI program in 6 hospitals without onsite cardiac surgery and then compared the PCI results in the pilot hospitals with results in 120 non-pilot hospitals. The pilot program qualification incorporated appropriate planning and rigorous hospital, operator, patient, and lesion selection criteria.
Read the detailed description
Design: The PCI California Audit Monitored Pilot with Offsite Surgery (PCI-CAMPOS) program is a prospective, multi-center pilot trial allowing elective PCIs at hospitals without on-site cardiovascular surgery in California. The pilot program was established by California Senate Bill No. 891 (SB 891) which was enacted in January 2009 authorizing the California Department of Public Health (CDPH) to set up a pilot program to allow California hospitals without surgery on-site to perform elective PCIs. The PCI-CAMPOS program was designed to compare PCI outcomes at the pilot hospitals with offsite cardiac surgery to PCI outcomes at established California hospitals with onsite cardiac surgery.
The CDPH requested pilot hospital applications in December 2009, selected 6 hospitals out of over 30 applicant hospitals in May 2010 and contracted with University of California, Davis (UCD) to train, audit, and monitor the program. The CDPH appointed a 12 member Advisory Oversight Committee (AOC) with 6 at-large members nominated by the California American College of Cardiology (CAACC) and 6 members from the pilot hospitals (1 principal investigator from each participating pilot hospital). The pilot program was funded by CDPH from fee assessments of participating pilot hospitals. The study was approved by the Institutional Review Board (IRB) at each pilot hospital and at the University of UCD coordinating center, and each patient is asked to provide written informed consent for pilot participation (unless unavailable in critically ill patients).
The National Cardiovascular Data Registry (NCDR®) CathPCI Registry (v. 4.3, 4.4) was selected as the data entry format for both pilot hospitals and non-pilot hospitals. The pilot PCI data is entered using the NCDR® CathPCI Registry v.4.3 and v.4.4 on an internet accessible UCD Velos server (Velos eResearch v9.1.2, Velos, Inc., Fremont, CA). The non-pilot hospitals enter their data using various NCDR® approved onsite software or the central NCDR® CathPCI v.4.3 and v.4.4 website. The pilot hospital data is entered within 72 hours of each procedure and immediately available to the PCI-CAMPOS coordinating center. The non-pilot data is entered individually or obtained from quarterly data harvests submitted to NCDR®. After masking patient, operator, and hospital identity, this non-pilot California NCDR® CathPCI registry data is downloaded annually from the NCDR® center to the UCD PCI-CAMPOS coordinating center. The UCD coordinating center performs all pilot audits and has full access to the pilot information. The UCD coordinating center performs all pilot and comparative analyses. Interim data summaries and analyses are presented to the full AOC for review at 6-12 month intervals throughout the study.
Outcomes: The pilot hospital outcomes are compared with hospital outcomes from non-pilot California hospitals performing either elective PCIs with surgery on-site or ST segment elevation myocardial infarction (STEMI) only PCIs. The non-pilot clinical data is obtained from the 120 California hospitals that submit their clinical data directly to the NCDR® data center and is used for the analysis of the data. Both the non-pilot and pilot data sets are analyzed and compared using SAS statistical software (version 9.3 for Windows, SAS Institute, Cary, NC).
Study Participants Hospitals: The non-pilot hospital group consists of all 120 California hospitals which submit PCI data directly to the NCDR® central database. For all elective PCIs, these hospitals have on-site surgery available for any post-PCI patients who require emergency coronary artery bypass graft (CABG) surgery.
The pilot hospital group consists of all 6 hospitals selected by the CDPH, which met the eligible hospital criteria as required by SB891 SEC.2. Section 1256.01 (c) (09/25/2008).
Operators: Operators are approved to perform procedures under the pilot program based on the operator criteria as required by SB891 SEC.2. Section 1256.01 (c) (09/25/2008). Pilot operators underwent training for the assessment of the operator, and the assessment of patient inclusion and exclusion requirements by UCD staff and were also were required to pass a competency exam. Non-pilot operators did not receive special training and their identity was masked to comply with NCDR® requirements.
Emergency (and salvage) pilot hospital PCIs are performed by any credentialed interventionalists at the pilot hospitals. Non-emergent (elective, urgent) PCIs are redirected to the pre-qualified pilot operators.
Coders: Data entry coders at each pilot hospital received an initial 1 day training session, followed by a competency exam. On-going training, telephone, and email access to the coordinating center are available throughout the program. Non-pilot coding is also performed by coders at each onsite hospital participating in the NCDR® CathPCI Registry.
Patients: All pilot hospital patients who consent and meet the SB891 SEC.2. Section 1256.01 (A through D) (09/25/2008) selection criteria for PCI at pilot hospitals are enrolled in the program. All patients with STEMI who present to the pilot hospitals are included in the STEMI PCI group. STEMI-excluded patients who are low to moderate risk for complications are included in the STEMI-excluded group. Patients deemed high-risk (both high lesion and patient risk) for complications are excluded from the pilot program. These high-risk patients are either discharged or transferred to non-pilot hospitals with onsite surgery for revascularization with PCI or CABG.
Pilot Protocol After completion of each PCI, the required information is entered online into the NCDR® CathPCI Registry v.4.3 and v.4.4 UCD server. All cases are then reviewed by the central coordinating site for data field completion and data consistency. All cases with complications [death, stoke, CABG, shock, congestive heart failure (CHF), cardiac arrest, IABP (intra-aortic balloon pump), perforation, significant dissection, tamponade, and new requirement for dialysis] and a randomized 10% of non-complication cases are then selected for a pilot-site audit that includes a review of all medical records and angiographic images. Audit reviews produce multiple queries that are transmitted to the hospital coders for discussion with operators. An iterative process eventually leads to a consensus agreement in most cases. In rare cases, when auditor-operator agreement is not achieved, the case is referred to the angiographic committee or to the AOC for a final determination. The patient and procedure data is stored on the Velos Server; the angiographic images are saved on an Xcelera R3.3L1 Server (Koninklijke Philips Electronics N.V.); and the statistical analyses are stored and performed on SAS software, version 9.3 for Windows (SAS Institute, Cary, NC).
Non-pilot Audits: California hospital PCI data that is submitted individually or at 3 month harvests to the NCDR® central database is reviewed for completeness and data accuracy by NCDR® and receives a red, yellow, or green light before acceptance. The vast majority of the hospitals in California that perform PCI participate in the NCDR CathPCI registry. The NCDR® in addition to employing robust data quality strategies for its participating hospitals also performs a limited number of site audits to directly assess data accuracy. The complete NCDR® non-pilot California data is downloaded annually to the UCD central site for comparison analysis. The downloaded data is masked to protect patient, operator, and hospital identity.
Statistical analysis: A PCI risk model has been developed and risk-adjusted endpoints are compared for the 6 pilot and 120 non-pilot hospital PCI procedures. To compare the demographic and clinical profiles and observed outcomes between CA-NCDR® (non-pilot)and PCI-CAMPOS (pilot), all continuous and categorical variables are reported as mean ± standard deviation (SD) or percentages, and compared with the t test or chi-square test (two tailed), respectively. The primary safety endpoint is a composite event which includes in-hospital death (regardless of length of stay), stroke, and/or patients who were transferred for an emergent CABG. The non-pilot data and the pilot data are merged as a single data source for development of the risk adjustment models for the composite outcome. With the combined data, we perform a bi-variable analysis to identify significant demographic and clinical risk factors for the composite outcome and serve as candidate risk factors for the multivariable logistic risk models. We developed both parsimonious and refined risk models with the combined data and use only non-pilot data for model validation purpose. All models are evaluated with the Hosmer-Lemeshow goodness-of-fit statistic. The c- statistic is reported as a measure of predictive power. The refined model is then used for computation of provider's expected and risk-adjusted composite event rates. A general linear model for analysis of variance (GLM/ANOVA) is used to compare observed, expected and risk-adjusted composite event rates between CA-NCDR® and PCI-CAMPOS hospitals. We further compute 95% confidence interval (CI) of provider's risk-adjusted composite event rate using the Poisson exact probability method for pilot and non-pilot hospitals and pilot operators. We determine provider's performance rating based on a comparison of the 95%CI of provider's risk-adjusted composite event rates and to the California average composite event rate that includes both CABG on-site and off-site hospitals. Two performance rating analyses are conducted for hospitals (or operators in pilot hospitals): (1) based on all PCIs and (2) based on PCIs with STEMI excluded. We also assess the correlation between provider's total and STEMI excluded PCI volume and risk-adjusted composite event rate among hospitals and operators in pilot hospitals. All reported p-values are 2-sided, and p-value < 0.05 are considered to be statistically significant. All statistical analyses are conducted at the UCD with the use of SAS software, version 9.3 for Windows (SAS Institute, Cary, NC).
- Conditions
- Coronary Artery Disease
- Being tested
- Percutaneous Coronary Intervention
- Keywords
- Percutaneous Coronary Intervention, Coronary Artery Disease, Angioplasty, Offsite cardiac surgery, Heart disease, Ischemic Heart Disease
- Medical subject headings
- Coronary Artery Disease, Heart Diseases, Myocardial Ischemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Percutaneous Coronary InterventionProcedure or surgery
Also called Coronary Angioplasty, Simple Angioplasty
| Study group | Role | What they receive |
|---|---|---|
| PCI at pilot hospitals | Active comparator | Percutaneous Coronary Interventions performed at pilot hospitals which do not have onsite cardiac surgery. Receives: Procedure: Percutaneous Coronary Intervention |
| PCI at non-pilot hospitals | Active comparator | Percutaneous Coronary Intervention performed at non-pilot hospitals which have onsite cardiac surgery or perform only primary PCIs for STEMI patients. Receives: Procedure: Percutaneous Coronary Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Composite safety endpoint (death, stroke, need for emergent CABG)
The number of subjects who had death, stroke or a need emergent CABG as a result of having PCI procedure performed.
Measured: participants will be followed for the duration of hospital stay, an expected average of 3 days.
Secondary outcomes (2)
Composite efficacy endpoint (<20% residual stenosis and post TIMI-3 flow)
The number of lesions treated that resulted in both a residual lesion stenosis of less than 20% and post procedure TIMI-3 flow.
Measured: participants will be followed for the duration of hospital stay, an expected average of 3 days.
AOC composite endpoint (in-hospital death and/or need for emergent CABG)
The number of subjects who had death or a need emergent CABG as a result of having PCI procedure performed.
Measured: participants will be followed for the duration of hospital stay, an expected average of 3 days.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Dec 2013 (estimated)
- Study startAug 2010
- Primary completionDec 2014
- Study completionFeb 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- More trials run by University of California, DavisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 5,609 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, Davis
- Sponsor type
- University, hospital or other
- Collaborators
- Clovis Community Hospital, Doctors Medical Center, Kaiser Permanente, Los Alamitos Medical Center, St. Rose Hospital, Sutter Roseville Medical Center
- Responsible party
- Sponsor
- Investigators
- William J Bommer, MD, Principal investigator, UC Davis Health SystemRohit Sundrani, MD, Principal investigator, Clovis Community Medical CenterStephen Arnold, MD, Principal investigator, Doctors Medical Center, San PabloSushil Karmarkar, MD, Principal investigator, Kaiser PermanenteSteven Forman, MD, Principal investigator, Los Alamitos Medical CenterAditya Jain, MD, Principal investigator, St Rose Hospital, HaywardGeorge Fehrenbacher, MD, Principal investigator, Sutter Roseville Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02022345
- Sponsor's protocol ID
- 301136
- Acronym
- PCI-CAMPOS
- Status last verified
- May 2017
- First submitted
- 17 Dec 2013
- Last updated
- 30 May 2017
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 30 May 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PCI California Audit Monitored Pilot With Offsite Surgery
- ClinicalTrials.gov ID
- NCT02022345
- Acronym / sponsor ID
- PCI-CAMPOS / 301136
- Conditions
- Coronary Artery Disease
- Keywords
- Percutaneous Coronary Intervention, Coronary Artery Disease, Angioplasty, Offsite cardiac surgery, Heart disease, Ischemic Heart Disease
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 5,609 participants (actual)
- Lead sponsor
- University of California, DavisUniversity, hospital or other
- Collaborators
- Clovis Community Hospital, Doctors Medical Center, Kaiser Permanente, Los Alamitos Medical Center, St. Rose Hospital, Sutter Roseville Medical Center
- Study start
- Aug 2010
- Primary completion
- Dec 2014 (actual)
- Study completion
- Feb 2015 (actual)
- First posted
- 27 Dec 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the introduction of Percutaneous Coronary Intervention without Onsite Surgery in the largest state, California (CA) began a pilot PCI program in 6 hospitals without onsite cardiac surgery and then compared the PCI results in the pilot hospitals with results in 120 non-pilot hospitals. The pilot program qualification incorporated appropriate planning and rigorous hospital, operator, patient, and lesion selection criteria.
Detailed description
Design: The PCI California Audit Monitored Pilot with Offsite Surgery (PCI-CAMPOS) program is a prospective, multi-center pilot trial allowing elective PCIs at hospitals without on-site cardiovascular surgery in California. The pilot program was established by California Senate Bill No. 891 (SB 891) which was enacted in January 2009 authorizing the California Department of Public Health (CDPH) to set up a pilot program to allow California hospitals without surgery on-site to perform elective PCIs. The PCI-CAMPOS program was designed to compare PCI outcomes at the pilot hospitals with offsite cardiac surgery to PCI outcomes at established California hospitals with onsite cardiac surgery.
The CDPH requested pilot hospital applications in December 2009, selected 6 hospitals out of over 30 applicant hospitals in May 2010 and contracted with University of California, Davis (UCD) to train, audit, and monitor the program. The CDPH appointed a 12 member Advisory Oversight Committee (AOC) with 6 at-large members nominated by the California American College of Cardiology (CAACC) and 6 members from the pilot hospitals (1 principal investigator from each participating pilot hospital). The pilot program was funded by CDPH from fee assessments of participating pilot hospitals. The study was approved by the Institutional Review Board (IRB) at each pilot hospital and at the University of UCD coordinating center, and each patient is asked to provide written informed consent for pilot participation (unless unavailable in critically ill patients).
The National Cardiovascular Data Registry (NCDR®) CathPCI Registry (v. 4.3, 4.4) was selected as the data entry format for both pilot hospitals and non-pilot hospitals. The pilot PCI data is entered using the NCDR® CathPCI Registry v.4.3 and v.4.4 on an internet accessible UCD Velos server (Velos eResearch v9.1.2, Velos, Inc., Fremont, CA). The non-pilot hospitals enter their data using various NCDR® approved onsite software or the central NCDR® CathPCI v.4.3 and v.4.4 website. The pilot hospital data is entered within 72 hours of each procedure and immediately available to the PCI-CAMPOS coordinating center. The non-pilot data is entered individually or obtained from quarterly data harvests submitted to NCDR®. After masking patient, operator, and hospital identity, this non-pilot California NCDR® CathPCI registry data is downloaded annually from the NCDR® center to the UCD PCI-CAMPOS coordinating center. The UCD coordinating center performs all pilot audits and has full access to the pilot information. The UCD coordinating center performs all pilot and comparative analyses. Interim data summaries and analyses are presented to the full AOC for review at 6-12 month intervals throughout the study.
Outcomes: The pilot hospital outcomes are compared with hospital outcomes from non-pilot California hospitals performing either elective PCIs with surgery on-site or ST segment elevation myocardial infarction (STEMI) only PCIs. The non-pilot clinical data is obtained from the 120 California hospitals that submit their clinical data directly to the NCDR® data center and is used for the analysis of the data. Both the non-pilot and pilot data sets are analyzed and compared using SAS statistical software (version 9.3 for Windows, SAS Institute, Cary, NC).
Study Participants Hospitals: The non-pilot hospital group consists of all 120 California hospitals which submit PCI data directly to the NCDR® central database. For all elective PCIs, these hospitals have on-site surgery available for any post-PCI patients who require emergency coronary artery bypass graft (CABG) surgery.
The pilot hospital group consists of all 6 hospitals selected by the CDPH, which met the eligible hospital criteria as required by SB891 SEC.2. Section 1256.01 (c) (09/25/2008).
Operators: Operators are approved to perform procedures under the pilot program based on the operator criteria as required by SB891 SEC.2. Section 1256.01 (c) (09/25/2008). Pilot operators underwent training for the assessment of the operator, and the assessment of patient inclusion and exclusion requirements by UCD staff and were also were required to pass a competency exam. Non-pilot operators did not receive special training and their identity was masked to comply with NCDR® requirements.
Emergency (and salvage) pilot hospital PCIs are performed by any credentialed interventionalists at the pilot hospitals. Non-emergent (elective, urgent) PCIs are redirected to the pre-qualified pilot operators.
Coders: Data entry coders at each pilot hospital received an initial 1 day training session, followed by a competency exam. On-going training, telephone, and email access to the coordinating center are available throughout the program. Non-pilot coding is also performed by coders at each onsite hospital participating in the NCDR® CathPCI Registry.
Patients: All pilot hospital patients who consent and meet the SB891 SEC.2. Section 1256.01 (A through D) (09/25/2008) selection criteria for PCI at pilot hospitals are enrolled in the program. All patients with STEMI who present to the pilot hospitals are included in the STEMI PCI group. STEMI-excluded patients who are low to moderate risk for complications are included in the STEMI-excluded group. Patients deemed high-risk (both high lesion and patient risk) for complications are excluded from the pilot program. These high-risk patients are either discharged or transferred to non-pilot hospitals with onsite surgery for revascularization with PCI or CABG.
Pilot Protocol After completion of each PCI, the required information is entered online into the NCDR® CathPCI Registry v.4.3 and v.4.4 UCD server. All cases are then reviewed by the central coordinating site for data field completion and data consistency. All cases with complications [death, stoke, CABG, shock, congestive heart failure (CHF), cardiac arrest, IABP (intra-aortic balloon pump), perforation, significant dissection, tamponade, and new requirement for dialysis] and a randomized 10% of non-complication cases are then selected for a pilot-site audit that includes a review of all medical records and angiographic images. Audit reviews produce multiple queries that are transmitted to the hospital coders for discussion with operators. An iterative process eventually leads to a consensus agreement in most cases. In rare cases, when auditor-operator agreement is not achieved, the case is referred to the angiographic committee or to the AOC for a final determination. The patient and procedure data is stored on the Velos Server; the angiographic images are saved on an Xcelera R3.3L1 Server (Koninklijke Philips Electronics N.V.); and the statistical analyses are stored and performed on SAS software, version 9.3 for Windows (SAS Institute, Cary, NC).
Non-pilot Audits: California hospital PCI data that is submitted individually or at 3 month harvests to the NCDR® central database is reviewed for completeness and data accuracy by NCDR® and receives a red, yellow, or green light before acceptance. The vast majority of the hospitals in California that perform PCI participate in the NCDR CathPCI registry. The NCDR® in addition to employing robust data quality strategies for its participating hospitals also performs a limited number of site audits to directly assess data accuracy. The complete NCDR® non-pilot California data is downloaded annually to the UCD central site for comparison analysis. The downloaded data is masked to protect patient, operator, and hospital identity.
Statistical analysis: A PCI risk model has been developed and risk-adjusted endpoints are compared for the 6 pilot and 120 non-pilot hospital PCI procedures. To compare the demographic and clinical profiles and observed outcomes between CA-NCDR® (non-pilot)and PCI-CAMPOS (pilot), all continuous and categorical variables are reported as mean ± standard deviation (SD) or percentages, and compared with the t test or chi-square test (two tailed), respectively. The primary safety endpoint is a composite event which includes in-hospital death (regardless of length of stay), stroke, and/or patients who were transferred for an emergent CABG. The non-pilot data and the pilot data are merged as a single data source for development of the risk adjustment models for the composite outcome. With the combined data, we perform a bi-variable analysis to identify significant demographic and clinical risk factors for the composite outcome and serve as candidate risk factors for the multivariable logistic risk models. We developed both parsimonious and refined risk models with the combined data and use only non-pilot data for model validation purpose. All models are evaluated with the Hosmer-Lemeshow goodness-of-fit statistic. The c- statistic is reported as a measure of predictive power. The refined model is then used for computation of provider's expected and risk-adjusted composite event rates. A general linear model for analysis of variance (GLM/ANOVA) is used to compare observed, expected and risk-adjusted composite event rates between CA-NCDR® and PCI-CAMPOS hospitals. We further compute 95% confidence interval (CI) of provider's risk-adjusted composite event rate using the Poisson exact probability method for pilot and non-pilot hospitals and pilot operators. We determine provider's performance rating based on a comparison of the 95%CI of provider's risk-adjusted composite event rates and to the California average composite event rate that includes both CABG on-site and off-site hospitals. Two performance rating analyses are conducted for hospitals (or operators in pilot hospitals): (1) based on all PCIs and (2) based on PCIs with STEMI excluded. We also assess the correlation between provider's total and STEMI excluded PCI volume and risk-adjusted composite event rate among hospitals and operators in pilot hospitals. All reported p-values are 2-sided, and p-value < 0.05 are considered to be statistically significant. All statistical analyses are conducted at the UCD with the use of SAS software, version 9.3 for Windows (SAS Institute, Cary, NC).
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| PCI at pilot hospitals | Active comparator | Procedure: Percutaneous Coronary InterventionPercutaneous Coronary Interventions performed at pilot hospitals which do not have onsite cardiac surgery. |
| PCI at non-pilot hospitals | Active comparator | Procedure: Percutaneous Coronary InterventionPercutaneous Coronary Intervention performed at non-pilot hospitals which have onsite cardiac surgery or perform only primary PCIs for STEMI patients. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (5 listed)
- clinically and angiographically significant coronary artery disease
- ability to perform PCI with equipment available at the local site
- not high-risk patient with a not high-risk lesion
- not high-risk patient with a high-risk lesion
- high-risk patient with a not high-risk lesion may be included in the pilot program upon confirmation that a cardiac surgeon and an operating room are immediately available if necessary
Key exclusion criteria (2 listed)
- high-risk patient with a high-risk lesion
- need for coronary artery bypass surgery
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Percutaneous Coronary InterventionAlso: Coronary Angioplasty, Simple Angioplasty | Procedure or surgery | PCI at non-pilot hospitals, PCI at pilot hospitals |
Primary outcome
Composite safety endpoint (death, stroke, need for emergent CABG)
Time frame: participants will be followed for the duration of hospital stay, an expected average of 3 days.
The number of subjects who had death, stroke or a need emergent CABG as a result of having PCI procedure performed.
2 secondary outcomes
Composite efficacy endpoint (<20% residual stenosis and post TIMI-3 flow)
Time frame: participants will be followed for the duration of hospital stay, an expected average of 3 days.
AOC composite endpoint (in-hospital death and/or need for emergent CABG)
Time frame: participants will be followed for the duration of hospital stay, an expected average of 3 days.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 May 2017.
Related trials for Coronary Artery Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
William J Bommer, MD principal investigator
UC Davis Health System
Rohit Sundrani, MD principal investigator
Clovis Community Medical Center
Stephen Arnold, MD principal investigator
Doctors Medical Center, San Pablo
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Percutaneous Coronary Intervention in people with Coronary Artery Disease, run by University of California, Davis at 6 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 May 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Composite safety endpoint (death, stroke, need for emergent CABG) (time frame: participants will be followed for the duration of hospital stay, an expected average of 3 days.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 May 2017.